Prevention of chemotherapy induced ovarian damage

Tuesday, December 29, 2015
We discuss methods for the prevention of chemotherapy-induced ovarian damage, including agents that act on the PI3K/PTEN/Akt follicle activation pathway, apoptotic pathways, the vascular system, and other potential methods of reducing chemotherapy-induced ovotoxicity.

Read More

Ovarian cortex transplantation Time to move on from experimental studies to open clinical application

Thursday, October 29, 2015

Authors:
Jacques Donnez, M.D., Ph.D., Marie-Madeleine Dolmans, M.D., Ph.D., César Diaz, M.D., Ph.D., Antonio Pellicer, M.D., Ph.D.…

Read More

Adolescent and adult uterine volume and uterine artery Doppler blood flow among subjects treated with bone marrow transplantation or chemotherapy in pediatric age A case control study

Friday, January 30, 2015
Bone marrow transplantation, total body irradiation, and busulfan use in pediatric patients are associated with subsequent reduction of uterine size and increased vascular resistance.

Read More

Oocyte donation outcome after oncological treatment in cancer survivors

Monday, December 29, 2014
The reproductive outcomes of oocyte donation from women cured of cancer are similar to those from women without previous cancer, regardless of cancer type.

Read More

Toward a better follow up of ovarian recovery in young women after chemotherapy with a hypersensitive antimullerian hormone assay

Wednesday, July 30, 2014
The hypersensitive PicoAMH assay, by its capacity to detect low levels of blood AMH, allows a more accurate prediction of menstrual cycle recovery in young women after chemotherapy.

Read More

Defining the specific reproductive effects of cancer therapies The burden is upon us

Tuesday, June 24, 2014
Reflections on "Impact of lymphoma treatments on spermatogenesis and sperm DNA: a multicenter prospective study from the CECOS network" by Bujan et al.

Read More

Impact of lymphoma treatments on spermatogenesis and sperm deoxyribonucleic acid A multicenter prospective study from the CECOS network

Monday, June 2, 2014
Lymphoma treatments had highly damaging effects on spermatogenesis and sperm chromatin quality. Mean pretreatment sperm concentrations were recovered at 12months after doxorubicin, bleomycin, vinblastine, darcarbacine (ABVD) or ABVD + radiotherapy, but at 24 months after doxorubicin, cyclophosphamide, vincristine, prednisone(CHOP) ormechlorethamine, oncovin, procarbazine, prednisone (MOPP) therapies.

Read More

Cancer treatment and male fertility effects of therapy and current and future management options

Thursday, October 31, 2013
Cancer treatments are detrimental to spermatogenesis. This series reviews effects of anticancer therapies on male fertility, current and future approaches to determine sperm health, and gives recommendations for patient management.

Read More

Fertility preservation and reproduction in patients facing gonadotoxic therapies a committee opinion

Thursday, October 31, 2013
Ethical considerations of preserving fertility after gonadotoxic treatment are discussed.

Read More

Biomarkers of chemotherapy induced testicular damage

Thursday, October 31, 2013
Chemotherapy treatment in men negatively impacts the male reproductive tract, and damage can potentially be transmitted to subsequent generations. Sensitive molecular biomarkers of injury are needed to ensure recovery of reproductive health.

Read More

Fertility preservation in patients undergoing gonadotoxic therapy or gonadectomy a committee opinion

Thursday, October 31, 2013
This document describes the responsibilities and strategies for fertility preservation in patients undergoing gonadotoxic medical therapy or radiation therapy or gonadectomy.

Read More

Multidrug resistant transport activity protects oocytes from chemotherapeutic agents and changes during oocyte maturation

Thursday, October 31, 2013
Oocytes have a vast repertoire of multidrug-resistant transporters. These protective effluxers change overall activity during maturation, and inhibition of these transporters increases cell susceptibility to toxicants.

Read More

Effects of chemotherapy and radiotherapy on spermatogenesis in humans

Thursday, October 31, 2013
Short- and long-term effects of radiotherapy, cytotoxic cancer chemotherapy, and biologic targeted therapies on human spermatogenesis are summarized and interpreted based on kinetics of spermatogenesis and recovery from stem cells.

Read More

Clinical guidelines for sperm cryopreservation in cancer patients

Thursday, October 31, 2013
In clinical guidelines for fertility preservation counseling in male cancer patients, issues of cell damage, contraception, and storage need to be highlighted before and after treatment as part of survivorship.

Read More

Granulocyte colony stimulating factor with or without stem cell factor extends time to premature ovarian insufficiency in female mice treated with alkylating chemotherapy

Friday, May 31, 2013
Treatment of mice with G-CSF with or without SCF protects ovarian follicle pool and extends time to premature ovarian insufficiency in mice treated with alkylating chemotherapy.

Read More

Restoration of ovarian activity and pregnancy after transplantation of cryopreserved ovarian tissue a review of 60 cases of reimplantation

Tuesday, April 30, 2013
A review of 60 cases of frozen-thawed ovarian tissue reimplantation is presented. Cryopreservation of ovarian tissue is the only option available for prepubertal girls and for women who cannot delay the start of chemotherapy.

Read More

Antimüllerian hormone the assessment of the ovarian reserve and the reproductive outcome of the young patient with cancer

Tuesday, April 30, 2013
We discuss the basis for the growing use of AMH in assessment of the ovarian reserve across the lifespan, and its emerging role in assessment before and after cancer treatment.

Read More

Pretreatment antimullerian hormone levels determine rate of posttherapy ovarian reserve recovery Acute changes in ovarian reserve during and after chemotherapy

Monday, February 4, 2013
Young women undergoing chemotherapy experience acute changes in ovarian reserve that recover in the months after therapy is completed. The rate of recovery of AMH is impacted by pretreatment levels.

Read More

Translate »